BioCentury | Jun 26, 2020
Distillery Therapeutics

MAP3K7, IL18R1 as targets in obesity-related cerebrovascular dysfunction

...dysfunction. In cultured rat aortic endothelial cells, an siRNA against IL18R1 increased levels of phosphorylated NOS3...
...the basilar artery, which supplies blood to the CNS; increased basilar artery levels of phosphorylated NOS3...
...kinase kinase kinase 7 (MAP3K7; TAK1); interleukin-18 receptor 1 (IL18R1; CD218a; IL18RA; IL-18Rα); endothelial cell nitric oxide synthase 3 (NOS3; eNOS...
BioCentury | Aug 9, 2019
Company News

Enbrel ruling lifts Amgen shares

A decision by the U.S. District Court for the District of New Jersey late Friday removed a key overhang on Amgen shares when it upheld two Enbrel patents at stake in a suit against Sandoz....
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Oct 11, 2018
Distillery Therapeutics


INDICATION: Hypertension Patient sample, cell culture, mouse and rat studies suggest inhibiting ENO1 could help treat pulmonary arterial hypertension (PAH) associated with other conditions. In pulmonary artery smooth muscle cell samples from patients with PAH...
BioCentury | Sep 14, 2018
Company News

Acorda loses Amprya appeal, reports Inbrija PDUFA delay

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $10.30 (37%) to $17.25 the week of Sept. 10 following setbacks related to multiple sclerosis drug Ampyra dalfampridine and Parkinson's disease candidate Inbrija levodopa inhalation powder (CVT-301). On Sept. 10,...
BioCentury | Sep 10, 2018
Company News

Acorda loses appeal to shield Ampyra from generic entry

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $6.75 (25%) to $20.80 Monday after the U.S. Court of Appeals for the Federal Circuit upheld a 2017 district court ruling that leaves multiple sclerosis drug Ampyra dalfampridine with no...
BioCentury | May 29, 2018
Preclinical News

IL-1 blockade to treat CAR T side effects

In a pair of papers published Monday in Nature Medicine, researchers from the Sloan Kettering Institute and the San Raffaele Hospital Scientific Institute suggest blocking the IL-1 receptor could help treat side effects of CAR...
BioCentury | May 23, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Patient sample and mouse studies suggest inhibiting NOS2 could help treat psoriatic arthritis. In peripheral blood mononuclear cells (PBMCs) from patients, levels of NOS2 were higher than in healthy volunteers. In a mouse...
BioCentury | Apr 17, 2018
Distillery Techniques


TECHNOLOGY: Gene profiling; tissue markers Tumor levels of a panel of 13 glycolysis-related genes could help predict responses to adoptive T cell therapies in melanoma patients. In tumors from an undisclosed number of melanoma patients...
Items per page:
1 - 10 of 798